Top Markets
#1 MowCat MowCat +48.24%
#2 Velvet Velvet +24.18%
#3 Bitway Bitway +22.81%
#4 aPriori aPriori +19.56%
#5 OVERTAKE OVERTAKE +18.77%
#6 Biconomy Biconomy +15.79%
#7 Derive Derive +14.39%
#8 Zerebro Zerebro +12.76%
#9 DODO DODO +11.91%
#10 Perle Perle +11.36%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
WPD Pharmaceuticals Inc. WPD Pharmaceuticals Inc.

WPD Pharmaceuticals Inc.

WBIO
Rank in Stocks #34463
WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver,... WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.
Share Price
$0.04895618
Last synced: 2025-03-18
Market Cap
$5.55M
Change (1 day)
-0.04%
Change (1 year)
0.00%
Country
CA
Trade WPD Pharmaceuticals Inc. (WBIO)

Category

Healthcare
P/E ratio for WPD Pharmaceuticals Inc. (WBIO)
P/E ratio as of 2026 TTM: 0
According to WPD Pharmaceuticals Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for WPD Pharmaceuticals Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.